Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

ed to the fair value of these rights. Excluding

these rights, the fair values of the assets and liabilities of the

joint venture as of March 31, 2008 were not significant.

(2) As of March 31, 2008, Other assets includes $80,100K for the fair

value of the five million shares of Isis Pharmaceuticals, Inc. common

stock that we purchased in February 2008.

GENZYME CORPORATION

RECONCILIATION OF GAAP TO NON-GAAP EARNINGS

For the Three Months Ended March 31, 2008

(Amounts in thousands, except per share data)

Dilution

Due to Premium on

Common Stock Strategic Equity

NON-GAAP Equivalents Investment

Income Statement

Classification:

Total revenues $1,100,061

Cost of products

and services sold $(265,799)

Selling, general and

administrative $(295,497)

Research and development $(180,312) $(69,900)

Amortization of

intangibles $-

Equity in income (loss)

of equity method

investments $188

Minority interest $463

Gains (losses) on

investments in equity

securities $775

Other $(160)

Investment income $14,870

Interest expense $(1,655)

Summary:

Income (loss) before

income taxes $372,934 $- $(69,900)

(Provision for) benefit

from income taxes $(112,039) $- $13,428

Net income (loss) $260,895
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Nev. , Sept. 17, 2014  PDL BioPharma, Inc. ... its independent registered accounting firm, Ernst & Young LLP ("EY") ... was confirmed in a letter delivered to the Company on ... on September 16, 2014.  PDL has issued ... "We have received a number of inquiries on the reason ...
(Date:9/17/2014)... PRINCETON, N.J. , Sept. 17, 2014 /PRNewswire/ ... developing targeted therapeutic devices to address infectious disease, cancer ... Sciences, Inc. (ESI), disclosed today that each company will ... Summit. On September 18 th , ... presentation entitled: "Exosomes: A Multiplexed Platform for Clinical Management." ...
(Date:9/17/2014)... NEWTOWN, Pa. , Sept. 17, 2014 ... services and eClinical Solutions, today announced three of its ... Conference for Clinical Data Management to be held ... Vegas, Nevada . The Company also announced the ... to raise overall quality in clinical trials acquired earlier ...
(Date:9/17/2014)... 2014 Alternative Fuels Americas, Inc. (AFAI) announced today ... Purpose Vehicle in partnership with Jatro Greentech, Inc., a ... The SPV shall be called AFAI Jatro Green Ethiopia and ... shareholder. The SPV shall pursue Jatropha planting and biofuels production ... Ethiopia . "Although we have experienced ...
Breaking Biology Technology:PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 3BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3
... of Wisconsin Hospital has completed its hospital-wide deployment ... final system being implemented in the hospital's pediatric units. ... is now operational in all 22 of the hospitals ... errors by 87 percent. This reduction is possible by ...
... growing up poor, money isn't the only solution to ... new study, the genes and warm support received from ... the cognitive and behavioral problems for which poverty puts ... May issue of the journal Child Development. , ,Numerous ...
... is part one of a three-part series focusing on the past, present ... up to WTNs interview with Nettles in March 2004. ... The Wisconsin Technology Network: Looking back over the past year, what accomplishments ... set of challenges you faced in your new position? , , ...
Cached Biology Technology:UW Hospital completes deployment of error-reducing technology 2UW Hospital completes deployment of error-reducing technology 3Study shows that genes can protect kids against poverty 2Study shows that genes can protect kids against poverty 3WTN exclusive interview with Commerce Secretary Cory Nettles (part 1) 2WTN exclusive interview with Commerce Secretary Cory Nettles (part 1) 3WTN exclusive interview with Commerce Secretary Cory Nettles (part 1) 4WTN exclusive interview with Commerce Secretary Cory Nettles (part 1) 5
(Date:9/17/2014)... great deal about complex social behavior by studying nonhuman ... teach too. , With their unusually large brains relative ... in a complex social environment---not merely in a large ... but in a dynamic setting of alliances and competitors. ... dolphins, whales, primates, and social carnivores, like hyenas and ...
(Date:9/16/2014)... of severe maternal morbidity amongst women in Australia ... new study published today (17 September) in ... . , Australians generally enjoy high standards of ... disparities exist, in particular between indigenous and non ... explore the independent impact of socioeconomic position on ...
(Date:9/16/2014)... Johns Hopkins neuroscientists have discovered the "molecular brakes" that ... ear cochleas of mice. These "hair cells" translate sound ... brain and are interpreted as sounds. If the arrangement ... , A summary of the research will be published ... 16. , "The proteins Hey1 and Hey2 act as ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2
... against antibiotic resistance, two new studies shed light on ... antibiotic attack, an understanding of which could lead to ... combat the growing problem of antibiotic resistance. The studies, ... membrane surrounding bacterial cells, will appear in the February ...
... large, clawed frog is helping Oregon Health & Science ... Fanconi anemia, a rare, genetic, cancer-susceptibility syndrome. , ... Biochemistry and Molecular Biology are the first to report ... frog, which goes by the Latin name Xenopus laevis, ...
... A novel enzyme in corn helps the plants defend themselves ... food, and ultimately killing them, according to researchers. The enzyme ... as the Bt toxin to prevent the pests from developing ... is found in insect-resistant strains of corn, and it breaks ...
Cached Biology News:Pair of studies offer new clues to combat antibiotic resistance 2Clawed frog helps Fanconi anemia research make leaps 2Clawed frog helps Fanconi anemia research make leaps 3Plants give pests sock in the gut 2Plants give pests sock in the gut 3